Paulo R. da S. R. Júnior
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paulo R. da S. R. Júnior has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Cleison C. Lobato
Graduate Program in Pharmaceutical Sciences, Federal University of Amapá, Macapa 68902-280, AP, Brazil
1 shared publication - Cleydson Breno Rodrigues dos Santos
Graduate Program in Pharmaceutical Sciences, Federal University of Amapá, Macapa 68902-280, AP, Brazil
1 shared publication - Gustavo Henrique Goulart Trossini
University of São Paulo
1 shared publication - Joaquin María Campos
Department of Pharmaceutical and Organic Chemistry, Faculty of Pharmacy, Institute of Biosanitary Research ibs. GRANADA, University of Granada, 18071 Granada, Spain
1 shared publication - Luciane Barros Silva
Laboratory of Modeling and Computational Chemistry, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil
1 shared publication - Lucio R. de Lima
Laboratory of Modeling and Computational Chemistry, Department of Biological and Health Sciences, Federal University of Amapá, Macapá 68902-280, AP, Brazil
1 shared publication
Latest Publications
- Open Access
- 21 August 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (8) , 1237
Identification of Potential Pteridin Reductase-1 Inhibitors for the Treatment of Leishmaniasis: A Bioinformatics Approach
Background/Objectives: Leishmaniasis is an infectious disease caused by digenetic protozoa of the genus Leishmania, transmitted by infected female sandflies of the Phlebotominae subfamily. Current treatments are limited, relying on drugs that were not specifically developed for this disease and are often associated with high toxicity and elevated costs. Among alternative therapeutic strategies, antifolate compounds have been investigated due to their ability to inhibit dihydrofolate reductase (DHFR), an enzyme essential for folate metabolism in the parasite. However, the parasite circumvents DHFR inhibition through the activity of pteridine reductase-1 (PTR-1), which maintains folate reduction and ensures parasite survival. In this context, this study aimed to identify potential PTR-1 inhibitors in Leishmania major through in silico approaches. Methods: The methodology included virtual screening of molecular databases, Tanimoto similarity analysis, pharmacokinetic and toxicological predictions, and biological activity evaluation in silico. The most promising compounds were further analyzed via molecular docking. Results: The virtual screening resulted in 474 molecules, of which 4 structures (M601, M692, M700, and M703) showed high potential as PTR-1 inhibitors in Leishmania major throughout all stages of the methodology employed, especially in the results of molecular docking where they exhibited strong binding affinities and significant interactions with key residues of the target enzymes. Conclusions: This work provides a solid foundation for advancing these molecules into experimental validation, contributing to the development of safer and more effective therapeutic alternatives for the treatment of leishmaniasis.
- 21 August 2025
- Published by MDPI AG in Pharmaceuticals
- Vol. 18 (8) , 1237
Open AccessIdentification of Potential Pteridin Reductase-1 Inhibitors for the Treatment of Leishmaniasis: A Bioinformatics Approach
Background/Objectives: Leishmaniasis is an infectious disease caused by digenetic protozoa of the genus Leishmania, transmitted by infected female sandflies of the Phlebotominae subfamily. Current treatments are limited, relying on drugs that were not specifically developed for this disease and are often associated with high toxicity and elevated costs. Among alternative therapeutic strategies, antifolate compounds have been investigated due to their ability to inhibit dihydrofolate reductase (DHFR), an enzyme essential for folate metabolism in the parasite. However, the parasite circumvents DHFR inhibition through the activity of pteridine reductase-1 (PTR-1), which maintains folate reduction and ensures parasite survival. In this context, this study aimed to identify potential PTR-1 inhibitors in Leishmania major through in silico approaches. Methods: The methodology included virtual screening of molecular databases, Tanimoto similarity analysis, pharmacokinetic and toxicological predictions, and biological activity evaluation in silico. The most promising compounds were further analyzed via molecular docking. Results: The virtual screening resulted in 474 molecules, of which 4 structures (M601, M692, M700, and M703) showed high potential as PTR-1 inhibitors in Leishmania major throughout all stages of the methodology employed, especially in the results of molecular docking where they exhibited strong binding affinities and significant interactions with key residues of the target enzymes. Conclusions: This work provides a solid foundation for advancing these molecules into experimental validation, contributing to the development of safer and more effective therapeutic alternatives for the treatment of leishmaniasis.